MyFinsight
Home
Blog
About
Short-term marketable
securities
$50,365K
Cash and cash
equivalents
$43,173K
(-51.18%↓ Y/Y)
Prepaid expenses and
other current assets
$1,869K
(-42.05%↓ Y/Y)
Deferred transaction
costs
$514K
Total current assets
$95,921K
(4.66%↑ Y/Y)
Other non-current
assets
$1,729K
(150.22%↑ Y/Y)
Operating lease
right-of-use assets
$1,389K
Restricted cash
$500K
(0.00%↑ Y/Y)
Total assets
$99,539K
(7.21%↑ Y/Y)
Total liabilities and
stockholders' equity
$99,539K
(7.21%↑ Y/Y)
Total stockholders'
equity
$57,672K
(8.58%↑ Y/Y)
Total liabilities
$41,867K
(5.39%↑ Y/Y)
Accumulated deficit
-$182,370K
(-32.05%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$73K
Additional paid-in capital
$240,113K
(25.57%↑ Y/Y)
Royalty obligation -
related party
$32,076K
(0.00%↑ Y/Y)
Total current
liabilities
$8,738K
(14.21%↑ Y/Y)
Operating lease
liabilities, long-term
$1,053K
Common stock, 0.0001
and 0.0001 par value...
$2K
(0.00%↑ Y/Y)
Accrued expenses and
other current...
$7,267K
(83.00%↑ Y/Y)
Accounts payable
$1,124K
(-69.46%↓ Y/Y)
Operating lease
liabilities, current
$347K
Back
Back
Balance Sheet
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)
source: myfinsight.com